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Abstract
Background: Deregulated c-Myc expression is a hallmark of several human cancers where it promotes proliferation 
and an aggressive tumour phenotype. Myc overexpression is associated with reduced activity of Rel/NF-κB, 
transcription factors that control the immune response, cell survival, and transformation, and that are frequently 
altered in cancer. The Rel/NF-κB family member NFKB2 is altered by chromosomal translocations or deletions in 
lymphoid malignancies and deletion of the C-terminal ankyrin domain of NF-κB2 augments lymphocyte proliferation.
Methods: Precancerous Eμ-Myc-transgenic B cells, Eμ-Myc lymphomas and human Burkitt lymphoma samples were 
assessed for Nfkb2 expression. The contribution of Nfkb2 to Myc-driven apoptosis, proliferation, and lymphomagenesis 
was tested genetically in vivo.
Results: Here we report that the Myc oncoprotein suppresses Nfkb2 expression in vitro in primary mouse fibroblasts 
and B cells, and in vivo in the Eμ-Myc transgenic mouse model of human Burkitt lymphoma (BL). NFKB2 suppression by 
Myc was also confirmed in primary human BL. Promoter-reporter assays indicate that Myc-mediated suppression of 
Nfkb2 occurs at the level of transcription. The contribution of Nfkb2 to Myc-driven lymphomagenesis was tested in vivo, 
where Nfkb2 loss was shown to accelerate lymphoma development in Eμ-Myc transgenic mice, by impairing Myc's 
apoptotic response.
Conclusions: Nfkb2 is suppressed by c-Myc and harnesses Myc-driven lymphomagenesis. These data thus link Myc-
driven lymphomagenesis to the non-canonical NF-κB pathway.
Background
Members of the Rel/NF-κB family of transcription fac-
tors, including RelA (p65), RelB, c-Rel, NF-κB1 [p105/
p50] and NF-κB2 [p100/p52], form homodimers and het-
erodimers that control aspects of T and B cell develop-
ment, proliferation and survival. The activity of NF-κB
dimers is held in check by dedicated inhibitors coined
IκBα or IκBβ, which bind to and sequester NF-κB in the
cytoplasm. Signals that activate NF-κB promote phos-
phorylation and ubiquitin-mediated destruction of the
IκBs, which are substrates of the upstream IκB kinases
Ikkα or Ikkβ (reviewed in [1-3]).
Regulation of NF-κB2 is unique amongst NF-κB family
members. First, p100 NF-κB2 protein harbors a C-termi-
nal ankyrin repeat domain that has intrinsic IκB activity,
whereas its Rel homology domain directs its nuclear
translocation, dimerization, and DNA binding functions.
Second, p100 is proteolytically processed to p52, an event
that requires Nik (NF-κB-inducing kinase) and Ikkα [4,5]
activity. Finally, targeted deletion of Nfkb2 in mice leads
to defects in B cell development and in lymphoid organo-
genesis [6].
NF-κB promotes cell survival and proliferation, and
alterations in this pathway, via chromosomal transloca-
tion or amplification, mutations, and deletions are com-
mon in cancer [7-9]. Important roles for NFKB2  in
lymphomagenesis have been implicated from studies in
both mouse and man. First, NFKB2 is a common target of
chromosomal rearrangements in human B lymphomas,
and these typically truncate the protein, generating con-
stitutively active nuclear forms [10,11] that have
increased transcriptional activity compared to p52
[12,13]. Furthermore, loss of the C-terminal ankyrin
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d o m a i n  o f  N F - κ B 2  i n  m i c e  r e s u l t s  i n  e n l a r g e d  l y m p h
nodes and augments lymphocyte proliferation [14].
The  c-MYC  gene (hereafter Myc) is the cellular
homolog of v-Myc, the transforming gene of the MC29
avian leukemia virus [15]. Myc oncoproteins (c-Myc, N-
Myc and L-Myc) are activated in ~70% of human malig-
nancies [16] and they function as basic helix-loop-helix-
leucine zipper transcription factors that coordinate cell
growth, division and metabolism [17-19]. In normal tis-
sue, the regulation of Myc transcription and turnover is
tightly controlled by mitogenic and growth inhibitory
cues [20], and in tumour cells these controls are fre-
quently lost, either by chromosomal translocations or
amplifications, or indirectly by mutations in regulatory
pathways.
The Rel/NF-κB pathway is suppressed in Myc-driven
human Burkitt lymphoma (BL) [21] and in Myc overex-
pressing precancerous B cells [22]. Here we report that
Myc suppresses Nfkb2 expression in B cells and show that
NF-κB2 contributes to Myc's apoptotic response that har-
nesses lymphomagenesis.
Methods
Mice and tumour analyses
Nfkb2 null mice (C57BL/6) [6] (obtained from Christo-
pher Hunter, University of Pennsylvania, Philadelphia,
P A ,  U S A )  w e r e  b r e d  w i t h  E μ - Myc  transgenic mice
(C57Bl/6) [23]. F1 Eμ-Myc;Nfkb2+/- offspring were bred to
Nfkb2+/- mice to obtain the desired Eμ-Myc;Nfkb2+/+ (n =
80) and Eμ-Myc;Nfkb2-/- (n = 44) cohort. Note that num-
bers of Eμ-Myc;Nfkb2-/- mice generated were lower than
those of Eμ-Myc;Nfkb2+/+ mice due to integration of the
Myc transgene on chromosome 19 where the Nfkb2 gene
resides (assessed by FISH analysis, data not shown). Ani-
mals were observed for signs of morbidity and tumour
development. Lymphomas were harvested, snap-frozen
in liquid nitrogen, and then processed for RNA and pro-
tein analyses.
With Institutional Review Board approval, and follow-
ing informed consent, lymphomas from 17 BL patients
were banked. RNA and protein were extracted from these
tumours (kindly provided by Drs. John Sandlund and
Mihaela Onciu, St. Jude Children's Research Hospital,
SJCRH, Memphis, TN). As a control, pooled peripheral
blood mononuclear cells (PBMC) from healthy donors
were enriched using CD19-MicroBeads (Miltenyi Bio-
tech, Bergisch-Gladbach, Germany) and RNA and pro-
tein were prepared.
Cell culture
Primary bone marrow (BM)-derived pre-B cells were cul-
tured as described [24]. B cells and mouse embryonic
fibroblasts (MEFs, cultured from E13.5-E14.5 embryos)
were infected with MSCV-Myc-ER™-IRES-GFP or
MSCV-Myc-IRES-GFP retroviruses as described [25]. To
activate Myc, Myc-ER™-expressing cells were treated with
2-μM 4-hydroxy-tamoxifen (4-HT) and lysed for protein
and RNA analyses. P493-6 human B cells were kindly
provided by G. Bornkamm (Helmholtz Zentrum
München, Munich, Germany) and were cultured with
tetracycline (Tet) or estrogen (both from Sigma-Aldrich,
Taufkirchen, Germany) as described [26]. To suppress
Myc  transcription, cells were treated with Tet (Sigma,
Taufkirchen, Germany) for 60 hr; to reactivate Myc cells
were then resuspended in medium lacking Tet. Transient
transfections of HeLa cells were performed using Lipo-
fectamine 2000 according to the manufacturer's instruc-
tions (Invitrogen, Carlsbad, CA).
FACS analysis and magnetic-activated cell sorting (MACS) 
of B cells
Rates of proliferation of bone marrow (BM) and splenic
B220+sIgM+ and B220+sIgM- cells were determined using
a Flow Kit as described by the manufacturer (BD Biosci-
ences Pharmingen, San Diego, CA). Briefly, animals were
injected intraperitoneally with 100 μl of 10 mg/ml BrdU
in sterile PBS. Animals were humanely sacrificed 12 hr
following injection and BM and spleen were harvested.
Red cells were lysed using ammonium chloride/potas-
sium bicarbonate solution. Cells were then resuspended,
incubated with antibody against B220 and sIgM (BD Bio-
sciences Pharmingen, San Diego, CA), washed and col-
lected by centrifugation. One million cells were further
processed and stained with anti-BrdU-FITC antibody,
and 5 × 105 cells were stained with Propidium iodide and
Annexin-V FITC antibody (Annexin-V-Fluor Kit, Roche
Applied Sciences, Indianapolis, IN). Following incubation
cells were washed, resuspended in PBS, and then analy-
sed by FACS. The remainder of the BM and spleen cells
were enriched for B cells by magnetic cell sorting with
B220 MicroBeads according to the manufacturer's
instructions (Miltenyi Biotech, Bergisch-Gladbach, Ger-
many) and were lysed for immunoblot or real-time PCR
analysis.
RNA preparation and analyses
RNA was prepared using the RNeasy kit (Qiagen, Valen-
cia, CA). For Affymetrix analyses, cRNA was synthesized
using the One-Cycle Target Labeling and Control
Reagent package (Affymetrix Inc., Santa Clara, CA) and
the reaction was probed to the 430A mouse Affymetrix
chip. The GCRMA normalization algorithm was applied
to all Affymetrix Chips using GeneSpring GX (v7.3).
GeneSpring Hierarchical Clustering (Similarity measure:
Pearson Correlation, Clustering Algorithm: Average
Linkage) was applied to those probe sets with signal
higher than median in at least one sample. For real-time
P C R ,  c D N A  w a s  p r e p a r e d  f r o m  1  μ g  R N A  u s i n g  t h eKeller et al. BMC Cancer 2010, 10:348
http://www.biomedcentral.com/1471-2407/10/348
Page 3 of 10
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-
time PCR was performed using an iCycler machine (Bio-
Rad) and the iTaq SYBR green kit (Bio-Rad). Data analy-
sis was performed by comparing Ct values with a control
sample set as 1. Sequences of primers are available upon
request.
Immunoblotting
Protein extracts (20 or 50 μg per lane) were electropho-
retically separated on SDS-PAGE gels, transferred to
membranes (Protran, Schleicher & Schuell, Dassel, Ger-
many) and blotted with antibodies specific for NF-κB2, c-
Myc, IKKα, Miz-1 (Santa Cruz Inc., Santa Cruz, CA) and
β-Actin (Sigma Chemicals, St. Louis, MO). Equal loading
of protein was demonstrated by Ponceau Red staining of
the nitrocellulose membranes following transfer.
Reporter assay
HeLa cells were co-transfected with an Nfkb2 promoter-
reporter construct (firefly luciferase, gift of R. M. Schmid,
Munich, Germany) and p65 (R. M. Schmid), c-Myc  or
GFP expression plasmids. Relative luciferase activity was
determined as described by the manufacturer (Promega,
Madison, WI), by calculating the ratio of firefly to co-
transfected renilla luciferase activity.
Results
The Rel/NF-κB pathway is suppressed in Myc-induced 
lymphomas
In the Eμ-Myc model of human B cell lymphoma disease
progression is characterized by a pre-neoplastic state in
which high proliferative rates of Eμ-Myc B cells are offset
by high levels of apoptosis, which is then disabled during
progression to the malignant state [24,27]. The Rel/NF-
κB pathway is suppressed in Myc-transgenic precancer-
ous B cells [22] and in human B lymphoma [21], yet the
underlying targets in this response are not resolved. To
address this issue we initially assessed the expression of
NF-κB components in B220+ splenic B cells of 4 week-old
precancerous Eμ-Myc transgenic mice (n = 5) and their
wild type littermate controls (n = 5), and in several (n =
13) Eμ-Myc  lymphomas. As expected, there were clear
increases in the levels of the established Myc targets Cad
[28] and Rcl [29], in precancerous Eμ-Myc  B cells, and
even more so in Eμ-Myc lymphomas, compared to their
levels in wild type splenic B cells (Figure 1, lower panel).
In contrast, there were reduced levels of nearly all
mRNAs encoding Rel/Nfkb factors, their inhibitors (Nfk-
bia and Nfkbib), and their upstream regulators in pre-
malignant Eμ-Myc  B cells compared to their levels
expressed in wild type B cells (Figure 1). Strikingly, this
response was significantly augmented in frank Eμ-Myc
lymphomas (Figure 1). Thus, Myc-mediated suppression
of the Rel/NF-κB pathway is augmented following the
switch to the neoplastic state.
Nfkb2 RNA and protein levels are suppressed by c-Myc
NFKB2 is the most frequently mutated Rel/Nfkb member
in human lymphoid malignancies [10,13]. We thus
assessed the effects of Myc on Nfkb2 expression in B cells
by real time PCR and western blot analyses of age-
matched littermate B220+ wild type and precancerous Eμ-
Myc  B cells. Consistent with the profiling data, Nfkb2
mRNA and NF-κB p100 and p52 protein levels were
markedly reduced in Eμ-Myc  bone marrow (BM) and
splenic B220+ B cells compared to wild type B cells (Fig-
ure 2a, b). Nfkb2 suppression was not due major differ-
ences in B cell subsets in the BM or spleens of wild type
versus pre-malignant Eμ-Myc mice (data not shown). Fur-
ther, there was a marked suppression of Nfkb2 transcripts
in all Eμ-Myc lymphomas (Figure 2c), and in all human
Burkitt lymphomas compared to pooled CD19+ control B
cells from healthy donors (Figure 2e). As expected, Myc
transcript and protein levels remained highly elevated in
manifest lymphoma [22,30]. Finally, both NF-κB p100
and p52 levels were reduced in the majority of Eμ-Myc
lymphomas (Figure 2d). Thus, Nfkb2 expression is sup-
pressed in Myc-driven lymphomas in mice and man.
Nfkb2 transcription is repressed by Myc
The regulation of Nfkb2 gene expression is complex and
involves positive and negative regulatory mechanisms,
including autoregulation [31,32]. In part its expression is
controlled by the activity of Ikkα [33]. However, we did
not observe significant changes of Ikkα protein in Eμ-Myc
lymphomas (Figure 2d). Thus, other mechanisms must
mediate the suppression of Nfkb2 by Myc in B cells.
To confirm that Nfkb2 expression in B cells was indeed
responsive to Myc, primary BM-derived B cells from wild
type mice were cultured and infected with the MSCV-
Myc-ER™-IRES-GFP retrovirus that expresses the tamox-
ifen-regulated, estrogen receptor chimeric Myc trans-
gene, Myc-ER™ [34], along with the gene encoding green
fluorescence protein (GFP) through the agency of an
internal ribosome entry site (IRES). GFP + cells were iso-
lated by FACS and expanded in culture in IL-7 medium.
These cells were then treated with 4-hydroxytamoxifen
(4-HT) to activate Myc-ER™. Notably, Myc activation led
to reductions in the levels of Nfkb2 transcripts (Figure
3a). To exclude possible indirect effects of Myc-induced
apoptosis on Nfkb2 expression, we also evaluated human
P493-6 B cells, which harbor a tetracycline (Tet) pro-
moter-regulated, conditional human c-Myc  transgene
[26] that is robustly induced following removal of Tet.
Notably the induction of c-Myc in this system led to
marked reduction in Nfkb2  mRNA levels (Figure 3b).Keller et al. BMC Cancer 2010, 10:348
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Finally, using the Myc-ER™ system, we also assessed
Nfkb2 mRNA in primary mouse embryonic fibroblasts
(MEFs). Again, Nfkb2 mRNA levels were reduced follow-
ing activation of Myc-ER™ (Additional File 1). Therefore,
the activation or overexpression of Myc suppresses Nfkb2
mRNA and protein expression.
To test whether Nfkb2 transcription was repressed by
Myc, we assessed the effects of Myc on Nfkb2 promoter
activity using luciferase reporter-based plasmids [32] in
HeLa cells. Notably, Myc significantly repressed Nfkb2-
promoter activity, and co-expression of Myc also inhib-
ited the robust induction of the Nfkb2 promoter by p65/
Figure 1 Myc targets the Rel/NF-κB network in precancerous B cells and lymphomas. Hierarchical clustering of Rel/Nfkb family members, up-
stream kinases that regulate the NF-κB pathway, and selected control genes was performed using RNA prepared from B220+ splenic B cells from five 
weanling-age wild type mice (wt), from five Eμ-Myc transgenic mice (Eμ-Myc), and from thirteen Eμ-Myc lymphomas. Probe set signals were normal-
ized to the mean across wt samples, and values of each individual sample are represented by a colour, with green corresponding to expression below, 
red corresponding to expression above, and black corresponding to expression equal to the wt mean expression.
Wt
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RelA (Figure 3c). Myc often represses transcription by
binding to and inhibiting the functions of the transcrip-
tional activator Miz-1 [35]. Since the Nfkb2  promoter
region contains an Initiator element (INR)-like sequence
and INRs mediate Miz-1-induced transcription [36], we
evaluated whether Miz-1 overexpression induced Nfkb2
transcripts. As expected, the direct Miz-1 target genes
p15INK4b and p21 [37,38] were induced by Miz-1 in pri-
mary MEFs, and Nfkb2  transcript levels were also
increased (Figure 3d). Thus, the Myc-mediated suppres-
sion of Nfkb2  transcription may involve disruption of
Miz-1 functions.
Nfkb2 impairs Myc-induced lymphomagenesis
The remarkable changes in the expression of components
of the Rel/NF-κB signalling pathway, and particularly the
Figure 2 Nfkb2 suppression in precancerous Myc-transgenic B cells and Myc-driven lymphomas. a) real-time PCR analysis of c-Myc, Nfkb2 and 
p21 mRNA levels in bone marrow (BM) and splenic (spleen) B220+ wild type (wt, grey bars) and precancerous Eμ-Myc (Eμ, black bars) B cells. Levels of 
mRNA are standardized to the expression of Ubiquitin (Ub), which is not regulated by Myc. * indicates p < 0.05. b) immunoblot analyses of the indicated 
proteins in control and precancerous Eμ-Myc B220+ B cells from bone marrow (BM) and spleen. c) real-time PCR analysis of Nfkb2 expression in ten Eμ-
Myc lymphomas or splenic wild type (wt) B220+ B cells. d) immunoblot analysis of NF-κB2 p100 and p52 expression in wild type (wt) and Eμ-Myc pre-
cancerous B220+ B cells and Eμ-Myc lymphomas. Nfkb2-/- and Nfkb1-/- B220+ B cells served as controls. e) real-time PCR analysis of NFKB2 expression in 
seventeen human Burkitt lymphoma samples compared to CD19+ control B cells. Levels of mRNAs were normalized to the expression of Ubiquitin (Ub).
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suppression of Nfkb2 by c-Myc, suggested that NF-kB2
might play critical roles in Myc-driven tumorigenesis. If
Myc-mediated reductions in Nfkb2 expression in Eμ-Myc
B cells were important for Myc-mediated lymphomagen-
esis, we reasoned that total loss of Nfkb2 should affect
lymphoma development. To test this hypothesis, Eμ-Myc
transgenic mice were mated to Nfkb2-/- mice [6] and F1
offspring were bred to Nfkb2+/- mice to obtain the desired
Eμ-Myc;Nfkb2+/+ and Eμ-Myc;Nfkb2-/- cohorts. These lit-
termates were then observed for lymphoma onset. Eμ-
Myc transgenic mice usually succumb to aggressive lym-
phoma within 4-8 months of birth [23]. As expected,
non-transgenic  Nfkb2-/- littermates showed no signs of
tumour development throughout their lifespan (data not
shown). Importantly, Eμ-Myc;Nfkb2-/-  transgenic dis-
played a moderately accelerated course of lymphoma
development and, accordingly, had a shorter lifespan,
with a median survival of 171 days compared to 205 days
median survival in their Eμ-Myc;Nfkb2+/+  littermates
(Figure 4a, p = 0.0307). The lymphomas that arose in Eμ-
Figure 3 Myc represses Nfkb2 transcription. a) SYBR-green real-time PCR analysis of Nfkb2 mRNA levels in primary, ex vivo cultured B cells infected 
with MSCV-Myc-ER™-IRES-GFP (Myc-ER) virus or MSCV-IRES-GFP (GFP) control virus. GFP-positive cells were sorted by flow cytometry, cultured, and 
treated with 4-hydroxytamoxifen (4-HT) for the indicated times. Levels of mRNAs are standardized to the expression of Ubiquitin (Ub). * indicates p < 
0.05. b) SYBR-green real-time PCR analysis of NFKB2 expression in human P493-6 cells treated with tetracycline (T, Myc-off state) ± estrogen (E, EBNA2-
on state) for the indicated times. c) HeLa cells were co-transfected with an Nfkb2 promoter-reporter construct (firefly luciferase) and the indicated ex-
pression plasmids. The relative luciferase activity was determined by calculatiing the ratio of firefly to co-transfected renilla luciferase activity. * indicates 
p < 0.05, ** indicates p < 0.01. d) expression of the indicated transcripts measured by real-time PCR following infection of primary MEFs with Miz-1 or 
control (Hygro) retroviruses. Levels of the indicated mRNA were standardized to the expression of Ubiquitin (Ub).
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Figure 4 Nfkb2 loss accelerates Myc-induced lymphomagenesis by impairing apoptosis. a) Effects of Nfkb2 deficiency on Myc-induced lym-
phomagenesis. The survival of Eμ-Myc transgenic littermates of the indicated Nfkb2 genotypes is shown. The differences in the rates of tumor inci-
dence between the Nfkb2+/+ and the Nfkb2-/- littermates is statistically significant (p = 0.0307). b) Eμ-Myc transgenic littermates of the indicated Nfkb2 
genotypes were injected with BrdU, and cells from bone marrow and spleen were harvested 12 hr later. BrdU-incorporation was analyzed using an 
antibody-dependent fluorescence assay. The bars show the mean percentage of cells in S phase ± SEM (three independent experiments). c) The apop-
totic index of the indicated genotypes was analyzed using an antibody dependent fluorescence assay. Annexin V+ B220+ cells of sIgM- or sIgM+ phe-
notype are shown. The bars represent the mean ± SEM from three independent experiments. * indicates p < 0.05.
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Myc;Nfkb2-/- transgenics were phenotypically identical to
those that arose in Eμ-Myc;Nfkb2+/+  mice, and full
necropsy and histopathological examination demon-
strated similar dissemination of disease in Eμ-
Myc;Nfkb2+/+  versus Eμ-Myc;Nfkb2-/-  mice (data not
shown). Thus, Nfkb2  loss accelerates Myc-driven lym-
phomagenesis without overtly affecting the disease phe-
notype.
Loss of the tumour suppressors p53 or Arf, which
mediate Myc's apoptotic response [25], dramatically
accelerates Myc-driven tumorigenesis [24,39]. By con-
trast, loss of regulators of the Myc-to-p27Kip1 pathway
that regulates Myc's proliferative response, such as E2f1
and Cks1, markedly delays lymphoma development and
prevents dissemination of disease [27,30,40]. We there-
fore assessed the effects of Nfkb2 loss on Myc's prolifera-
tive and apoptotic responses. To evaluate effects on Myc's
proliferative response BrdU was injected intraperitone-
ally into 4-week old Eμ-Myc;Nfkb2+/+ and Eμ-Myc;Nfkb2-/
- littermates and after 12 hr B220+sIgM+ and B220+sIgM-
cells were assessed for their S phase indices. Loss of
Nfkb2 had essentially no effects on Eμ-Myc B cell prolifer-
ation in either BM or spleen (Figure 4b). To address the
effects of Nfkb2  loss on Myc-induced apoptosis, the
apoptotic indices of pre-cancerous B220+ B cells from Eμ-
Myc;Nfkb2+/+ and Eμ-Myc;Nfkb2-/- mice were determined
by staining with anti-Annexin V-FITC and propidium
iodide. There was a significant reduction in the apoptotic
indices of sIgM- splenic Eμ-Myc;Nfkb2-/- B cells compared
to matched sIgM- splenic B cells from Eμ-Myc;Nfkb2+/+
mice (Figure 4c). The sIgM- population of B cells are
those most prone to Myc-induced apoptosis in the Eμ-
Myc model [41]. Thus, the accelerated lymphoma devel-
opment manifest in Eμ-Myc;Nfkb2-/- mice is associated
with an impaired apoptotic response.
Discussion
Members of the Rel/NF-κB family can, depending on cell
context, act as either tumour suppressors or oncogenes
[42]. A hallmark of human Burkitt lymphoma, and of pre-
malignant B cells and lymphomas of Eμ-Myc mice, is sup-
pression of the Rel/NF-κB signaling pathway [21,22,43].
These findings, and those reported herein, suggest that
Myc-induced suppression of this important immune and
inflammatory regulatory network contributes to lym-
phomagenesis.
Myc executes most of its functions as a transcription
factor that regulates a large cast of target genes (see: Myc
Cancer Gene http://www.myc-cancer-gene.org; reviewed
in [44,45]). Genes suppressed by Myc include those
encoding proteins involved in apoptosis [19] and growth
arrest [46]. Various mechanisms of transcriptional
repression by Myc are operational. Amongst these, Myc-
mediated inhibition of Miz-1 transcriptional activity by
Myc:Max heterodimers is clearly a central pathway by
which Myc overrides cell growth control [44-46]. Growth
arrest genes, including p21  [47], p15 [37] and Gadd45
[48], are elevated in c-Myc-/- cells and are suppressed in
cells that overexpress Myc. In B lymphocytes Myc is
required for normal B cell proliferation and CD40-medi-
ated proliferation [49]. CD40 signalling has been shown
to activate the non-canonical NF-κB pathway [50]. It was
therefore tempting to speculate that the suppression of
Nfkb2 by Myc controls the expansion of B cells under
normal and/or stressful conditions. Unexpectedly, in the
Eμ-Myc model precancerous B cell proliferation was not
significantly reduced upon Nfkb2 loss.
The recently described autoimmune disease in mice
having constitutive NF-κB2 p52 in lymphocytes is associ-
ated with increased B cell proliferation and a defective
response to apoptotic stimuli [51]. Further, in transgenic
mice that express the lymphoma-associated NF-κB2
mutant p80HT, B cell proliferation is not affected but
lymphomas do occur, and B cells from these mice are
resistant to apoptosis [52]. In the Eμ-Myc model loss of
Nfkb2 does not affect Myc's proliferative response, but it
does disable the apoptotic response in sIgM- Eμ-Myc B
cells, which are the subset that is most prone to Myc-
induced apoptosis in this mouse model [41]. Thus, at
least in the context of Myc overexpression, which is
clearly a hallmark of most rapidly dividing human malig-
nancies including lymphoma and leukemia, NF-κB2 con-
tributes to the apoptosis response and, accordingly, Nfkb2
loss accelerates Myc-driven lymphomagenesis. In addi-
tion to Myc suppression of the non-canonical pathway
discovered herein, others have recently attributed tumour
suppressive functions to classical NF-κB activity in the
context of Myc-induced lymphoma [53]. Therefore, both
the canonical and the non-canonical NF-κB pathway
f u n c t i o n  a s  t u m o u r  s u p p r e s sors in Myc-transformed
murine lymphoma and most likely human Burkitt lym-
phoma.
Conclusions
Our work identifies Nfkb2 as a Myc repression target, and
Myc appears to regulate both basal and stimulated Nfkb2
transcription. Suppression of the non-canonical NF-κB
pathway provides a selective advantage to Myc-trans-
formed lymphomas and thus contributes to lymphom-
agenesis. These findings have implications for the
development of therapies against Myc-dependent
tumours.
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